Fresenius Follows US Denosumab Filing With EU Acceptance
EMA Accepts Firm’s Applications For Biosimilar Rivals To Prolia And Xgeva
Executive Summary
Fresenius Kabi’s denosumab biosimilar filing has been accepted by the European Medicines Agency, coming hot on the heels of a US submission.